A Randomized, Double-blind, Placebo-controlled, Dose-escalation, Single and Multiple Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0142-0002 Administered Subcutaneously to Subjects With Rheumatoid Arthritis
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2016
At a glance
- Drugs NN 8555 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 15 Dec 2011 Actual patient number is 65 according to ClinicalTrials.gov.
- 15 Dec 2011 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 15 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.